We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Erasca Inc (ERAS) USD0.0001

Sell:$6.17 Buy:$6.18 Change: $0.18 (3.01%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.18 (3.01%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.18 (3.01%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. The Company’s lead product candidates are ERAS-007 and ERAS-601, which together comprise its first MAPKlamp. ERAS-007 is designed to be an oral inhibitor of ERK1/2, which has been evaluated as a single agent in a Phase I clinical trial in patients with advanced solid tumors completed by Asana. ERAS-601 is an oral SHP2 inhibitor, which is under first-in-human Phase I clinical trial, FLAGSHP-1. The Company’s SHP2 inhibitor is designed to block oncogenic signal transduction and delay the onset of therapeutic resistance, which has the potential to serve as a backbone of combination therapy against RAS/MAPK pathway altered cancers.

Contact details

10835 Road To The Cure, Suite 140
United States
+1 (858) 4656511

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$729.93 million
Shares in issue:
121.59 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jonathan Lim
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • David Chacko
    Chief Financial Officer
  • Michael Varney
    Director, Chair of Research and Development
  • Lisa Tesvich-bonora
    Chief People Officer
  • Brian Baker
    Senior Vice President - Finance
  • Nik Chetwyn
    Senior Vice President - Operations
  • Chandra Lovejoy
    Senior Vice President - Regulatory Affairs
  • Robert Shoemaker
    Senior Vice President - Research
  • David Luo
    Vice President - Clinical Research and Operations
  • Bao Truong
    Vice President and Program Team Leader

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.